Thomas W. LeBlanc, MD, MA, MHS and Arif H. Kamal, MD, MBA, MHS
Clinical trials should assess patients’ distress and test interventions to address it, just as they assess adverse events and test novel therapeutic agents.
AMA J Ethics. 2017;19(5):460-466. doi:
10.1001/journalofethics.2017.19.5.stas1-1705.
Hilary Daniel joins Ethics Talk to discuss her article, coauthored with Courtney Perlino and Dr Amy B. Cadwallader: “Which Drugs Should Be on the Essential Medicines List?”
Physicians should not only avoid forming personal relationships with drug reps but must also acquire and apply numeracy skills and information management strategies to critically evaluating drug reps’ information.
AMA J Ethics. 2015;17(8):729-733. doi:
10.1001/journalofethics.2015.17.8.ecas1-1508.
Elizabeth Lee Daugherty, MD, MPH and Douglas B. White, MD, MA
Opportunities to advance scientific knowledge may arise during humanitarian crises, but their presence does not justify suspension of the ethical foundations governing human subjects research.
Research is needed to understand mental health effects of cancer at diagnosis, throughout treatment and the post-treatment phases, and in survivorship.
AMA J Ethics. 2017;19(5):486-492. doi:
10.1001/journalofethics.2017.19.5.msoc2-1705.
Physicians have an ethical responsibility to caregivers whose psychological distress is caused by their experience of the patient’s illness and treatment.
AMA J Ethics. 2017;19(5):493-500. doi:
10.1001/journalofethics.2017.19.5.msoc3-1705.
Amanda Fakih, MHSA and Kayte Spector-Bagdady, JD, MBE
Testing everyone for everything identifies more fetal conditions, but confusion persists about whether clinicians should leave screening decisions to patients.
AMA J Ethics. 2019;21(10):E858-864. doi:
10.1001/amajethics.2019.858.